52791-03-4 Usage
General Description
Methyl 7-Nitro-1,4-benzodioxane-6-carboxylate is a chemical compound with the molecular formula C11H9NO7. It is a nitro-substituted ester of 1,4-benzodioxane-6-carboxylic acid, and is commonly used as a reagent in organic synthesis. Methyl 7-Nitro-1,4-benzodioxane-6-carboxylate is known to have potential pharmacological activities, and thus has been the subject of research in drug development. It is important to handle this chemical with caution, as it may be harmful if ingested or inhaled, and can cause irritation to the skin and eyes. Methyl 7-Nitro-1,4-benzodioxane-6-carboxylate is also known to be a potential environmental hazard and should be disposed of properly according to regulations.
Check Digit Verification of cas no
The CAS Registry Mumber 52791-03-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,7,9 and 1 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 52791-03:
(7*5)+(6*2)+(5*7)+(4*9)+(3*1)+(2*0)+(1*3)=124
124 % 10 = 4
So 52791-03-4 is a valid CAS Registry Number.
52791-03-4Relevant articles and documents
BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS
-
Paragraph 0143-0144; 0157; 0162-0163; 0176; 0192; 0197-0198, (2021/04/10)
The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according to formula (I): whe
METHODS AND COMPOUNDS FOR ANTIMICROBIAL INTERVENTION
-
Page/Page column 68, (2010/01/07)
The present invention provides Wall Teichoic Acid biosynthesis inhibitors such as compound 1835F03 (targocil) and related synthetic analogs. The invention also provides pharmaceutical compositions thereof and methods for treating bacterial infection and t
SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS
-
Page 72, (2010/02/04)
This invention provides compounds of formula (1) wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
